RxDoctor Payments DataLook up a doctor →

Angela Stinson, APRN

Nurse Practitioner · Somerset, KYNPI 1528050853

Payments from drug & device makers

$12,474in general payments, 2019–2025

Across 764 payments — averaging $16.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
  • Johnson & Johnson$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$939
  • Phathom Pharmaceuticals, Inc.$760
  • Sanofi$595
  • plus $3K from 23 others

What the payments were for

  • Food & beverage$12,36099%
  • Education$1141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,474 in reported general payments places this provider in the 95th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$66,016
Medicare patients
550
Services billed
842

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin136$417,529
CreonLipase/Protease/Amylase128$284,962
Humira(Cf) PenAdalimumab40$273,669
LinzessLinaclotide221$161,878
IbsrelaTenapanor Hcl69$127,979
EntyvioVedolizumab11$97,355
Humira(Cf)Adalimumab13$88,553
Dexlansoprazole DrDexlansoprazole169$31,169
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate25$29,179
AciphexRabeprazole Sodium18$28,531
TrulancePlecanatide33$27,481
DexilantDexlansoprazole24$16,602
Mesalamine ErMesalamine18$13,870
MovantikNaloxegol Oxalate26$10,585
Budesonide EcBudesonide24$6,953

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess, Humira(Cf)$3,019$535,393362 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$2,884$445,010169 claims
Ardelyx, Inc.Ibsrela$200$127,97969 claims
Takeda Pharmaceuticals U.S.A., Inc.Entyvio, Dexilant$939$113,95735 claims
Redhill Biopharma Inc.Movantik$11$10,58526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Somerset

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →